Ahead of the launch of its LPLDL cholesterol-reducing strain next month, OptiBiotix Health plc (LON:OPTI) has sold a batch of capsules to a German distributor.
OptiBiotix said it has agreed to supply 100,000 units of LPLDL to HLH BioPharma Vertriebs, a company that has more than 20 years' experience in the distribution of probiotic and natural products under the brand names Lactobact and Casa Sana.
HLH is one of Europe's leading suppliers of probiotics to the pharmacy market.
READ the OptiBiotix investment case
WATCH OptiBiotix boss talk about the transition process
The bulk capsules will be packaged and branded as part of HLH's market leading Lactobact brand.
OptiBiotix said these pre-launch sales will provide moderate amounts of income for the group, and would raise industry awareness of LPLDL as a functional component in a wide range of consumer healthcare and pharmaceutical products.
"We see this as the first step in building sales and market presence of LPLDL as the 'Intel' inside a wide range of products for cardiovascular health across both consumer and pharmaceutical markets around the world,” explained Stephen O’Hara, chief executive officer of OptiBiotix.
“This creates the opportunity for multiple revenue streams from sales of the strain, white label, and branded products in different presentations and formulations to meet the needs of a diverse range of national and international markets," he added.
Shares in OptiBiotix were up 0.8% at 73.1p at midday after the release this morning of the company’s full year results.